Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE
2024-511822-30-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of allogeneic fecal microbiota in Crohn's disease, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical remission at week 52 without flare. Planned start Oct 2024; status: authorised.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-511822-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511822-30-00.